{Reference Type}: Journal Article
{Title}: Abnormal expression of oxylipins and related synthesizing/signaling pathways in inflammatory bowel diseases.
{Author}: Ben-Mustapha Y;Rekik R;Ben-Fradj MK;Serghini M;Sanhaji H;Ben-Ahmed M;Boubaker J;Feki M;
{Journal}: Prostaglandins Leukot Essent Fatty Acids
{Volume}: 202
{Issue}: 0
{Year}: 2024 Jul 1
{Factor}: 3.015
{DOI}: 10.1016/j.plefa.2024.102628
{Abstract}: We investigated selected oxylipins and related synthesizing/signaling pathways in 28 patients with Crohn's disease (CD), 19 patients with ulcerative colitis (UC), and 39 controls. Plasma and mucosal PUFA/oxylipin profiles were analyzed by LC-MS/MS. mRNA expression of 5, 12 and 15-lipooxygenases, FPR2/ALXR, FFAR4/GPR120, annexin A1, and interleukin-10 were analyzed by qRT-PCR. Oxylipin profile and related metabolic pathways were altered in both CD and UC patients. The patterns were characterized by increased prostaglandins, leukotrienes, and lipoxins and overexpression of 5-lipoxygenase, FPR2/ALXR, annexin A1, and interleukin-10 genes, but decreased n-3 PUFAs and 18-hydroxyeisapentaenoic acid. The gene of 15-lipoxygenase was under-expressed mainly in UC patients. CD and UC are associated with unbalanced n-6 ​​and n-3 derivatives and pro-inflammatory and anti-inflammatory/pro-resolving mediators favoring the former compounds. The findings suggest that oxylipins engage in the pathophysiology of the diseases. Targeting oxylipin's metabolic pathways would be a promising therapy for inflammatory bowel diseases.